Multiple Myeloma With Symptomatic Progression
Videos
Multiple Myeloma With Symptomatic Progression
Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the toxicities that are associated with PARP inhibitors in ovarian cancer.
ALK-Translocated Non-Small Cell Lung Cancer With Bone Metastases
Recurrent Metastatic Gastrointestinal Stromal Tumor
High-Risk Primary Myelofibrosis
Hydroxyurea Resistant Polycythemia Vera
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
2
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
3
Targeting the IL-2 Pathway to Overcome Immunotherapy Resistance in Melanoma
4
Revumenib Maintenance After Allogeneic SCT Shows Feasibility in AML
5